Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Medistem Industry/Academia Collaboration Leads to Nanotechnology Based "Cancer Vaccine": Peer-Reviewed Publication Demonstrates New Method of Treating Prostate Cancer Based on Nanoparticle-Loaded Dendritic Cells

Abstract:
Medistem Inc. (PINKSHEETS: MEDS) announced today it has co-authored a peer-reviewed publication disclosing a new approach to stimulating the immune system to kill tumor cells using a novel nanotechnology-based approach.

Medistem Industry/Academia Collaboration Leads to Nanotechnology Based "Cancer Vaccine": Peer-Reviewed Publication Demonstrates New Method of Treating Prostate Cancer Based on Nanoparticle-Loaded Dendritic Cells

San Diego, CA | Posted on April 14th, 2012

In the publication (PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. International Journal of Nanomedicine, 7: 1475, 2012) Medistem and a team of collaborators demonstrated that nanoparticles could be used to deliver molecules found on tumors to specific cells of the immune system called "dendritic cells." These nanoparticle-loaded dendritic cells were then able to stimulate other cells of the immune system to directly kill tumors in the test tube and also in mice bearing prostate cancer.

"Cellular therapy is a clinical reality, for example, the company Dendreon developed the first therapeutic FDA-approved cancer vaccine Sipuleucel-T (Provenge) that is currently being used for treatment of patients with hormone-resistant prostate cancer. The data we published today provides ways of optimizing treatments such as Provenge," said Dr. Vladimir Bogin, President and Chairman of Medistem. "By using nanotechnology to specifically educate dendritic cells to activate the immune system in patients, it may be possible to develop more effective ways of treating cancer by leveraging the body's own resources."

The senior author of the publication, Dr. Boris Minev, is faculty at the Moores Cancer Center, and at the Division of Neurosurgery of the University of California, as well as Director of Immunotherapy and Translational Oncology at Genelux Corporation. Additional collaborators included the Laboratory of Biomaterials and Nanotechnology, University of California Riverside, the Division of Neurosurgery, of University of California Los Angeles, and the Chemistry Department at San Diego State University.

"For more than 4 years, I have thoroughly enjoyed collaborating with the Medistem Team, in areas including treatment of multiple sclerosis, cancer immunotherapy, rheumatoid arthritis, and now nanotechnology. The common theme of our collaboration is leveraging the body's own resources as a therapeutic," said Dr. Boris Minev. "In addition to the recently announced clinical trials for Medistem's Endometrial Regenerative Cell (ERC) universal donor stem cell, I am looking forward to clinical translation of other products of our collaboration."

To date Medistem and Dr. Minev have published 12 peer-reviewed papers together. Dr. Minev was co-author on Medistem's original paper describing human use of the ERC in patients with multiple sclerosis (click here for link www.translational-medicine.com/content/pdf/1479-5876-7-15.pdf), as well as several other basic research and clinical publication. Medistem has filed US provisional patent # 61/592,636 covering naturally-derived nanoparticles generated by ERC.

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

####

For more information, please click here

Contacts:
Lisa Brock
Director of Investor Relations

503.381.4618

Medistem Inc.
9255 Towne Centre Drive
Suite 450
San Diego, CA 92122
www.medisteminc.com
Twitter: @medistem

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Oxford Instruments and Dresden High Magnetic Field Laboratory collaborate to develop HTS magnet technology components for high field superconducting magnet systems June 29th, 2016

Texas A&M Chemist Says Trapped Electrons To Blame For Lack Of Battery Efficiency: Forget mousetraps — today’s scientists will get the cheese if they manage to build a better battery June 28th, 2016

Building a smart cardiac patch: 'Bionic' cardiac patch could one day monitor and respond to cardiac problems June 28th, 2016

New, better way to build circuits for world's first useful quantum computers June 28th, 2016

Nanomedicine

Building a smart cardiac patch: 'Bionic' cardiac patch could one day monitor and respond to cardiac problems June 28th, 2016

Nanoscientists develop the 'ultimate discovery tool': Rapid discovery power is similar to what gene chips offer biology June 25th, 2016

Nanotechnology and math deliver two-in-one punch for cancer therapy resistance June 24th, 2016

Self-assembling icosahedral protein designed: Self-assembling icosahedral protein designed June 22nd, 2016

Announcements

Oxford Instruments and Dresden High Magnetic Field Laboratory collaborate to develop HTS magnet technology components for high field superconducting magnet systems June 29th, 2016

Texas A&M Chemist Says Trapped Electrons To Blame For Lack Of Battery Efficiency: Forget mousetraps — today’s scientists will get the cheese if they manage to build a better battery June 28th, 2016

Building a smart cardiac patch: 'Bionic' cardiac patch could one day monitor and respond to cardiac problems June 28th, 2016

New, better way to build circuits for world's first useful quantum computers June 28th, 2016

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers

Texas A&M Chemist Says Trapped Electrons To Blame For Lack Of Battery Efficiency: Forget mousetraps — today’s scientists will get the cheese if they manage to build a better battery June 28th, 2016

Building a smart cardiac patch: 'Bionic' cardiac patch could one day monitor and respond to cardiac problems June 28th, 2016

New, better way to build circuits for world's first useful quantum computers June 28th, 2016

Yale researchers’ technology turns wasted heat into power June 27th, 2016

Research partnerships

Superheroes are real: Ultrasensitive nonlinear metamaterials for data transfer June 25th, 2016

Soft decoupling of organic molecules on metal June 23rd, 2016

FEI and University of Liverpool Announce QEMSCAN Research Initiative: University of Liverpool will utilize FEI’s QEMSCAN technology to gain a better insight into oil and gas reserves & potentially change the approach to evaluating them June 22nd, 2016

Tailored DNA shifts electrons into the 'fast lane': DNA nanowire improved by altering sequences June 22nd, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic